Press release -
Meet us at the NLSDays 2018
CTC are happy to announce that we will attend the Nordic Life Science Days 2018 in Stockholm, the 10-12th of September.
Our Customer Relations team will be at booth A06 to meet both new and familiar faces. We are eager to answer your questions and to tell you more about our true full-service package in early phase clinical trials, including clinical conduct at our first-in-human approved clinic.
The CTC team is open for scheduled meetings as well as spontaneous small talks.
We look forward to meeting you!
NLSDays offers networking and knowledge for anyone interested in the Nordic Life science, biotechnologies, pharmaceuticals, medical devices and e-health business. NLSDays are expecting over 1000 international delegates with a focus on quality meetings.
NLSDays is a SwedenBIO event, produced by Bionordic Services AB.
Topics
- Business enterprise, General
Categories
- nlsdays
CTC Clinical Trial Consultants AB is a full-service CRO with focus on clinical conduct. Our mission is to facilitate clinical and translational research by providing our customers with cost-effective advice, conduct and reporting of clinical trials. We have four different departments: Clinic, Clinical Operations, Pharmacovigilance and Biometrics, all supported by independent quality assurance management.
Our head office and Phase I units are located in Uppsala comprising 28 beds of which 12 are hospital beds in a first-in-human approved research unit whereas our two professional sites for multicenter studies (SMOs) are found in Uppsala and Linköping. We have our own subject database for recruitment of both healthy volunteers and special patient populations.
CTC was founded in 2011 and has successfully conducted over 200 industry sponsored clinical trials for start-up companies as well as for international pharmaceutical companies and CROs. Our track record includes first-in-human, food effect, drug interaction, bioequivalence, bioavaliability and biosimilar studies, new drug delivery systems, medical device, PET/MR, QT and Phase IIa studies.
